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Summary   1 
Bacterial infections have remained significant despite our advances in the 2 
development of a plethora of disinfectants as well as antimicrobial chemotherapy. 3 
This is in part due to our incomplete understanding of the prevalence of bacterial 4 
pathogens in the environmental and clinical settings. Several lines of evidence suggest 5 
that Acanthamoeba is one of the most ubiquitous/resilient protists that also acts as a 6 
host/reservoir for pathogenic microbes. Thus targeting the hardy host, which harbour 7 
microbial pathogens, offer a potential avenue to counter infection transmission, 8 
particularly hospital/community-acquired infections. This will complement existing 9 
approach of applying disinfectants that are targeted against bacterial pathogens 10 
directly.  11 
 12 
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Introduction   1 
“Superbugs” or multiple-drug resistant (MDR) microbes, in particular MDR 2 
bacteria is a growing public health threat that represents an enormous challenge for 3 
healthcare providers, given the few antimicrobials at our disposal. Antibacterial 4 
disinfection strategies have had some success but failed to eradicate MDR bacteria 5 
completely from healthcare settings. Thus, there is a need to develop alternative 6 
strategies to combat MDR bacteria. Several lines of evidence show that 7 
Acanthamoeba is one of the most widely distributed protists that also acts as a 8 
host/reservoir for microbes including potential infectious agents (Khan, 2009). The 9 
ability of a unicellular amoeba to host another microbe within itself is an 10 
extraordinary trait that require convoluted interactions. In such interactions, if both 11 
organisms are pathogenic, they are referred to as hyperparasites, and the relationship 12 
is known as hyperparasitic relationship that can benefit one or both organisms. For 13 
example, bacterial survival intracellular of amoebae may lead to their evolutionary 14 
gain of pathogenicity, immune evasion strategies, or bacterial protection from hostile 15 
environments. For latter, the ability of Acanthamoeba to form hardy cysts can provide 16 
MDR bacteria shelter against common disinfectants within the clinical settings. Cyst 17 
is a dormant form, i.e., non-feeding, non-replicating form, during which amoeba 18 
encloses itself in a double-walled structure. Cyst can remain viable following 19 
exposure to high temperature (65°C), 50ppm chlorine, 200 mJ per cm2 and known to 20 
resist commonly used disinfectants that include alcohol- or chlorine-based products, 21 
even though such disinfectants can prove effective against MDR bacteria (Aksozek et 22 
al., 2002; Khan, 2009). This may explain our inability to completely eradicate MDR 23 
bacteria from healthcare settings. Thus, it is suggested that targeting the host, i.e., 24 
amoeba cysts, that harbour MDR bacteria or possibly other microbial pathogens could 25 
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prove to be a pivotal tool to eliminate pathogens within hospitals (Siddiqui and Khan, 1 
2013). This area of research is well-timed and relevant, given a significant rise in 2 
hospital-, nursing-, and community-based infections, worldwide (Nordmann et al., 3 
2007; Alanis, 2005; Blondeau, 2013). 4 
MDR bacteria: old enemy presenting new challenges 5 
MDR bacteria are resistant to multiple antimicrobial drugs. Increase in 6 
resistance has led to emergence of extensively drug-resistant (XDR) bacteria as well 7 
as pan drug-resistant (PDR) bacteria. Infections due to drug resistant bacteria are 8 
challenging and expensive. Data from the CDC, USA show that multiple-drug 9 
resistant (MDR) microbes affect approximately two million people per year in the 10 
United States alone (CDC, 2013).  Some examples of MDR bacteria include: 11 
Staphylococcus aureus derivatives such as MRSA, Streptococcus pneumonia, 12 
Klebsiella spp., Enterococcus spp., and Mycobacterium tuberculosis, to name a few 13 
(Nordmann et al., 2007; Alanis, 2005; Blondeau, 2013). For developing countries 14 
MDR bacteria are of increasing concern; as antibiotic-resistant bacteria can be 15 
overlooked resulting in increased trend of antibacterial resistance, as witnessed in K. 16 
pneumoniae (referred as NDM-1) (Yong et al., 2009; Oberoi et al., 2013; Trivedi and 17 
Sabnis, 2009). Many developed countries have managed to reduce the antibacterial 18 
resistance occurrence and showed reduction, by regulating antibacterial consumption 19 
(Barbosa and Levy, 2000), however compliance is poor in developing countries. The 20 
wide application of antibacterials, both for clinical applications as well as 21 
agriculture/farming/animal feed is exacerbating the emerging trends of antibacterial 22 
resistance (Marshall and Levy, 2011; Snitkin et al., 2012).  23 
Disturbingly, even the most advanced institutions show limited success in 24 
eradicating superbugs (Levy, 1998; CDC). In a recent case of MDR-K. pneumoniae 25 
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(Snitkin et al., 2012) precautions were taken to halt the spread of infection to other 1 
patients. These included patient isolation, hand hygiene practices, restricted traffic 2 
and strict use of protective clothing, dedicated equipment, extensive cleaning with 3 
bleach, once vacated. Nonetheless, this common bacterial infection spread to other 4 
patients within the institution. Consequent intervention measures comprised 5 
demolishing drains, extensive use of hydrogen peroxide via a robot. Yet the infection 6 
spread to 17 other patients, six of whom deceased, highlighting the ability of bacteria 7 
to resist available disinfection practices (Nordmann et al., 2007; Levy, 1998). While 8 
the current disinfection strategies are inefficient, a plethora of bacteria have gained 9 
resistance to several antibiotics and are now considered MDR bacteria or 10 
“superbugs”. According to the CDC, MRSA and C. difficile alone, contribute to 11 
14,000 and 19,000 deaths annually in the USA alone (CDC). Worryingly, patients are 12 
increasingly concerned of visiting hospitals for common diseases or surgeries as the 13 
visits may lead to contracting MDR bacteria (Madeo, 2011). 14 
World Health Organisation stresses antimicrobial resistance as one of the most 15 
critical threat to the global health (WHO, 2002). Furthermore there is an increasing 16 
trend of infections even within the community setting (Klein and Smith, 2009). 17 
Centers for Disease Control and Prevention approximates that 12% of MRSA-infected 18 
patients are now community-associated (CDC). The aim is to introduce novel 19 
strategies/approaches to counter MDR bacteria, as the use of antibacterial 20 
disinfectants in healthcare settings is ineffective in eradicating MDR bacteria.  21 
Emerging strategies to tackle MDR bacteria   22 
At present, the main strategy to avoid bacterial infection transmission and 23 
spread is isolation and the use of disinfectants (Levy, 1998; Madeo, 2011; Levy, 24 
2000). In general, cleaning solution is chlorine-based such as 5% solution of sodium 25 
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hypochlorite (Eckstein et al., 2007). However, this is ineffective against 1 
Acanthamoeba cysts (Coulon et al., 2010), which could be harbouring and thus 2 
protecting MDR bacteria to commonly used antibacterial disinfectnat (Briancesco et 3 
al., 2005). Hence, for effective eradication of pathogens, the focus cannot be on one 4 
organism. In fact, it is quite the reverse. As diseases often have various and 5 
perplexing factors with diverse etiologies and environmental niches that need to be 6 
explored to understand the complex subtleties of infection transmission. Much more 7 
work is required to understand how pathogens are refuged in the environment/clinical 8 
setting despite the use of powerful antibacterial disinfectants, so that preventative 9 
measures can be designed appropriately. Other factors that facilitate transmission of 10 
microbes to, and between people, must be determined to design innovative 11 
interventional measures.   12 
In his landmark observation, Rowbotham witnessed that Acanthamoeba is a 13 
host and a reservoir for Legionnaires’-causative agent, L. pneumophila by showing 14 
that L. pneumophila survives and multiplies inside the amoeba (Rowbotham, 1980). 15 
Now it is well known that Acanthamoeba can host viral, bacterial, protists, and yeats 16 
(Khan, 2009; La Scola et al., 2003; Greub and Raoult, 2004). Acanthamoeba is one of 17 
the most omnipresent protist and it can also cause infections (Khan, 2009). It has two 18 
stages in its life cycle, an actively growing stage, termed as the trophozoite stage, and 19 
a non-dividing stage, termed as the cyst stage. Cysts are non-dividing with little 20 
metabolic activity, possess a hardy shell and are air-borne, making them highly 21 
resistant to harsh environments, as well as chemicals (Fig. 1) (Aksozek et al., 2002; 22 
Lloyd et al., 2001; Turner et al., 2000). The ability of Acanthamoeba to differentiate 23 
into a dormant cyst form (with negligible metabolic activity) is a remarkable property, 24 
as it allows amoeba to evade drugs, which target functional aspect of the parasite such 25 
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as respiration, RNA/DNA transcription, translation, protein synthesis and 1 
modifications, intracellular trafficking, cell wall/membrane synthesis, motility etc. 2 
Notably, the majority of available drugs target function at physiologically-relevant 3 
conditions, making them obsolete against the inactive cyst form. In addition, the 4 
hardy shell of the cyst form protects Acanthamoeba against high levels of radiation, 5 
temperatures, disinfectants such as chlorine etc. (Aksozek et al., 2002; Lloyd et al., 6 
2001; Turner et al., 2000). Intriguingly, cysts can remain viable for decades (Mazur et 7 
al., 1995) and can be airborne (Rodriguez-Zaragoza and Magana-Becerra, 1997). 8 
Surprisingly, a complete understanding of the biochemical profile of the cyst walls of 9 
Acanthamoeba remains unknown, making it challenging to eradicate them effectively 10 
and/or rationally develop disinfectants/biocides to degrade the outer walls and target 11 
the masked trophozoite together with any intracellular pathogens. The ability of 12 
Acanthamoeba to host pathogenic microbes such as MDR bacteria, protect them 13 
under harsh conditions (disinfectants), and contribute to pathogen transmission 14 
presents a major threat to the public and of great concern. This “hyperparasitism” 15 
(parasite within a parasite) is likely contribute indirectly to infections (La Scola et al., 16 
2003; Greub and Raoult, 2004). The details of these interactions are incompletely 17 
understood, but it is postulated that the inability of pathogenic microbes (such as non-18 
spore forming bacteria) to resist harsh conditions led to evolutionary need to assist 19 
with a protective host, to remain viable when enduring adverse conditions. The hardy 20 
cysts can shelter microbes against hostile conditions and allows them to survive harsh 21 
conditions such as disinfectants in clinical settings, possibly leading to spread to 22 
vulnerable population. Thus, it is rational to hypothesize that amoeba is a potential 23 
niche of pathogenic microbes, and plays a role in their spread to the susceptible 24 
population. Recently, the prevalence of Acanthamoeba and superbugs in a clinical 25 
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setting was determined (Siddiqui et al., 2013). Both bacteria and Acanthamoeba were 1 
found to co-exist in the hospital environment. Furthermore, antibiotic susceptibility 2 
showed that all bacterial isolates recovered were MDR. In addition to present 3 
practices, interventional strategies targeting amoebae should be investigated to 4 
eliminate pathogenic microbes.  5 
The way forward: Translating research to clinical practice   6 
Acanthamoeba cysts can persist as viable cysts for over 20 years while 7 
retaining their pathogenicity and can be air-borne (Mazur et al., 1995; Sriram et al., 8 
2008), so it is particularly challenging to target these cysts that may be harbouring 9 
MDR bacteria. Previous studies have shown that hydrogen peroxide-based contact 10 
lens disinfectants are useful against trophozoites and one-week old cysts as compared 11 
to other solutions (Johnston et al., 2009). As per FDA, it is a safe oxidizing agent 12 
against microbial pathogens. It can sterilize objects as well as airborne microbes. This 13 
may explain why cleaning with vapourised form of hydrogen peroxide-based 14 
disinfectants inhibited the chances of a patient developing antibiotic-resistant bacterial 15 
colonization by a staggering 80 percent suggesting its effectiveness (Doan et al., 16 
2012; Passaretti et al., 2013; Zoutman et al., 2011; Gatti et al., 1998). We sanction 17 
that this effect is due to antiamoebic effects of hydrogen peroxide, in addition to its’ 18 
anti-bacterial properties. We propose that the use of hydrogen peroxide will target 19 
both the “terror cells” i.e. the MDR bacteria and the host harbouring them, i.e., 20 
amoeba.  21 
Due to its toxicity and instability, there is a need to find safe, and effective 22 
agents targeting both MDR bacteria and amoebal host with long-term shelf-life, cost-23 
effectiveness and practicality, to be appropriate for healthcare settings; particularly in 24 
developing countries. Since Acanthamoeba is a Trojan horse of the microbial world 25 
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including potential pathogens (Huws et al., 2006), we anticipate that disinfectants that 1 
are effective in killing both Acanthamoeba as well as bacteria will be of enormous 2 
worth for applications in clinical settings. Future studies will test such disinfectants 3 
with dual action to determine their effectiveness in eradicating superbugs from 4 
clinical settings.      5 
In summary, these findings suggest that strategies targeting the hardy host, i.e., 6 
Acanthamoeba that harbour microbial pathogens offer a potential avenue to counter 7 
infectious diseases, particularly hospital/community-acquired infections. The 8 
proposed strategy will complement existing approach of applying disinfectants that 9 
are targeted against bacterial pathogens directly. These findings should be of interest 10 
to public health officials and/or policy makers, medical practitioners, and the 11 
scientific community. 12 
 13 
Declaration of conflicting interest: The authors declare that there are no conflicts of 14 
interest. 15 
Funding: This research received no specific grant from any funding agency in the 16 
public, commercial, or not-for-profit sectors. 17 
 18 
References 19 
Aksozek, A., McClellan, K., Howard, K., Niederkorn, J.Y., Alizadeh, H., 2002. 20 
Resistance of Acanthamoeba castellanii cysts to physical, chemical, and 21 
radiological conditions. J. Parasitol. 88, 621-623. 22 
Alanis, A.J., 2005. Resistance to antibiotics: are we in the post-antibiotic era? Arch. 23 
Med. Res. 36, 697-705.  24 
 10 
Antibiotic Resistance Threats in the United States. 2013. Centers for Disease Control 1 
and Prevention. http://www.cdc.gov/drugresistance/threat-report-2013/  2 
Barbosa, T.M., Levy, S.B., 2000. The impact of antibiotic use on resistance 3 
development and persistence. Drug Resist. Updat. 3, 303-311.  4 
Blondeau, J., 2013. Gram-negative superbugs: inappropriate antimicrobial therapy 5 
and mortality. Expert Rev. Clin. Pharmacol. 6, 347-349.  6 
Briancesco, R., Veschetti, E., Ottaviani, M., Bonadonna, L., 2005. Peracetic acid and 7 
sodium hypochlorite effectiveness in reducing resistant stages of 8 
microorganisms. Cent. Eur. J. Public Health 13, 159-162. 9 
Centers for Disease Control and Prevention. http://www.cdc.gov/   10 
Coulon, C., Collignon, A., McDonnell, G., Thomas, V., 2010. Resistance of 11 
Acanthamoeba cysts to disinfection treatments used in health care settings. J. 12 
Clin. Microbiol. 48, 2689-2697.  13 
Doan, L., Forrest, H., Fakis, A., Craig, J., Claxton, L., Khare, M., 2012. Clinical and 14 
cost effectiveness of eight disinfection methods for terminal disinfection of 15 
hospital isolation rooms contaminated with Clostridium difficile 027. J. Hosp. 16 
Infect. 82, 114-121.  17 
Eckstein, B.C., Adams, D.A., Eckstein, E.C., Rao, A., Sethi, A.K., Yadavalli, G.K., 18 
Donskey, C.J., 2007. Reduction of Clostridium difficile and vancomycin-19 
resistant Enterococcus contamination of environmental surfaces after an 20 
intervention to improve cleaning methods. BMC Infect. Dis. 7, 61. 21 
Gatti, S., Cevini, C., Bruno, A., Penso, G., Rama, P., Scaglia, M., 1998. In vitro 22 
effectiveness of povidone-iodine on Acanthamoeba isolates from human cornea. 23 
Antimicrob. Agents Chemother. 42, 2232-2234. 24 
 11 
Greub, G., Raoult, D., 2004. Microorganisms resistant to free-living amoebae. Clin. 1 
Microbiol. Rev. 17, 413-33. 2 
Huws, S.A., Smith, A.W., Enright, M.C., Wood, P.J., Brown, M.R., 2006. Amoebae 3 
promote persistence of epidemic strains of MRSA. Environ. Microbiol. 8, 1130-4 
1133. 5 
Johnston, S.P., Sriram, R., Qvarnstrom, Y., Roy, S., Verani, J., Yoder, J., Lorick, S., 6 
Roberts, J., Beach, M.J., Visvesvara, G., 2009. Resistance of Acanthamoeba 7 
cysts to disinfection in multiple contact lens solution. J. Clin. Microbiol. 47, 8 
2040-2045. 9 
Khan, N.A., 2009. Acanthamoeba: Biology and Pathogenesis. Caister Academic 10 
Press, UK.    11 
Klein, E., Smith, D.L., Laxminarayan, R., 2009. Community-associated Methicillin-12 
Resistant Staphylococcus aureus in Outpatients, United States, 1999 – 2006. 13 
Emerg. Infect. Dis. 15, 1925-1930.  14 
La Scola, B., Audic, S., Robert, C., Jungang, L., de Lamballerie, X., Drancourt, M., 15 
Birtles, R., Claverie, J.M., Raoult, D., 2003. A giant virus in amoebae. Science 16 
299, 2033.   17 
Levy, S.B., 1998. The challenge of antibiotic resistance. Scien. Am. 278, 46-53. 18 
Levy, S.B., The 2000 Garrod lecture. Factors impacting on the problem of antibiotic 19 
resistance. J. Antimicrob. Chemother. 49, 25-30. 20 
Lloyd, D., Turner, N.A., Khunkitti, W., Hann, A.C., Furr, J.R., Russell, A.D., 2001. 21 
Encystation in Acanthamoeba castellanii: development of biocide resistance. J. 22 
Eukaryot. Microbiol. 48, 11-16. 23 
Madeo, M., 2011. Cleaning the hospital environment--a focus on Difficil-S. Br. J. 24 
Nurs. 20, 690-693. 25 
 12 
Marshall, B.M., Levy, S.B., 2011. Food Animals and Antimicrobials: Impacts on 1 
Human Health. Clin. Microbiol. Rev. 24, 718-733. 2 
Mazur, T., Hadaś, E., Iwanicka, I., 1995. The duration of the cyst stage and the 3 
viability and virulence of Acanthamoeba isolates. Trop. Med. Parasitol. 46, 106-4 
108.  5 
Nordmann, P., Naas, T., Fortineau, N., Poirel, L., 2007. Superbugs in the coming new 6 
decade; multidrug resistance and prospects for treatment of Staphylococcus 7 
aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr. Opin. 8 
Microbiol. 10, 436-440.  9 
Oberoi, L., Singh, N., Sharma, P., Aggarwal, A., 2013. ESBL, MBL and Ampc β 10 
lactamases producing sSuperbugs - Havoc in the intensive care units of Punjab 11 
India. J. Clin. Diagn. Res. 7, 70-73. 12 
Passaretti, C.L., Otter, J.A., Reich, N.G., Myers, J., Shepard, J., Ross, T., Carroll, 13 
K.C., Lipsett, P., Perl, T.M., 2013. An evaluation of environmental 14 
decontamination with hydrogen peroxide vapor for reducing the risk of patient 15 
acquisition of multidrug-resistant organisms. Clin. Infect. Dis. 56, 27-35.  16 
Rodriguez-Zaragoza, S., Magana-Becerra, A., 1997. Prevalence of pathogenic 17 
Acanthamoeba (Protozoa:Amoebidae) in the atmosphere of the city of San Luis 18 
Potosi, Mexico. Toxicol. Ind. Health 13, 519-526. 19 
Rowbotham, T.J., 1980. Preliminary report on the pathogenicity of Legionella 20 
pneumophila for freshwater and soil amoebae. J. Clin. Pathol. 33, 1179-1183. 21 
Siddiqui, R., Khan, N.A., Infection control strategy by killing drug-resistant bacteria. 22 
Pathog. Global Health 107, 215-216.  23 
 13 
Siddiqui, R., Sagheer, M., Khan, N.A., 2013. Prevalence of Acanthamoeba and 1 
superbugs in a clinical setting: coincidence or hyperparasitism. Parasitol Res. 2 
112, 1349-1351.      3 
Snitkin, E.S., Zelazny, A.M., Thomas, P.J., Stock, F., 2012. NISC Comparative 4 
Sequencing Program Group, Henderson DK, Palmore TN, Segre JA. Tracking a 5 
hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-6 
genome sequencing. Sci. Transl. Med. 4, 148. 7 
Sriram, R., Shoff, M., Booton, G., Fuerst, P., Visvesvara, G.S., 2008. Survival of 8 
Acanthamoeba cysts after desiccation for more than 20 years. J. Clin. Microbiol. 9 
46, 4045-4048.   10 
Trivedi, T.H., Sabnis, G.R., 2009. Superbugs in ICU: is there any hope for solution? J. 11 
Assoc. Physician. India 57, 623-625. 12 
Turner, N.A., Russell, A.D., Furr, J.R., Lloyd, D., 2000. Emergence of resistance to 13 
biocides during differentiation of Acanthamoeba castellanii. J. Antimicrob. 14 
Chemother. 46, 27-34. 15 
WHO. 2002. Use of antimicrobials outside human medicine and resultant 16 
antimicrobial resistance in humans. World Health Organization 17 
http://www.who.int/mediacentre/factsheets/fs268/en/index.html. 18 
Yong, D., Toleman, M.A., Giske, C.G., Cho, H.S., Sundman, K., Lee, K., Walsh, 19 
T.R., 2009. Characterization of a new metallo-beta-lactamase gene, bla(NDM-20 
1), and a novel erythromycin esterase gene carried on a unique genetic structure 21 
in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents 22 
Chemother. 53, 5046-5054.  23 
 14 
Zoutman, D., Shannon, M., Mandel, A., 2011. Effectiveness of a novel ozone-based 1 
system for the rapid high-level disinfection of health care spaces and surfaces. 2 
Am. J. Infect. Control. 39, 873-879.  3 
 4 
Figure legends 5 
Figure 1. Representative transmission electron micrographs showing a complete 6 
double-walled cyst of Acanthamoeba castellanii belonging to the T4 genotype 7 
(American Type Culture Collection, ATCC 50492). IM is inner membrane; and OM 8 
is outer membrane. Bar = 2 μm. 9 
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